PATH vs TCBIO · P/E 19, rev $1.61B vs P/E 5.2, $3.31B cap
Uipath Inc (PATH) versus Texas Capital Bancshares, Inc. (TCBIO) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Texas Capital Bancshares, Inc. (TCBIO) is a banks - regional company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
TCBIO does not have a complete income-statement cache yet.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. TCBIO currently screens at market cap $3.31B and trailing P/E 5.2.
Not investment advice. Open the PATH and TCBIO stock pages for the full models.
Not investment advice.